Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 3, 2012, Pages

  Rolinski, Michal ^a   Fox, Chris ^b   Maidment, Ian ^c   Mcshane, Rupert ^d  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^c KENT AND MEDWAY NHS AND SOCIAL CARE PARTNERSHIP TRUST   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE; TACRINE; CARBAMIC ACID DERIVATIVE; INDAN DERIVATIVE; NEUROPROTECTIVE AGENT; PIPERIDINE DERIVATIVE;

ADVERSE EVENT; BEHAVIOR DISORDER; BEHAVIOR DISORDER ASSESSMENT; CLINICAL ASSESSMENT; COGNITION; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXPERIENCE; HUMAN; MINI MENTAL STATE EXAMINATION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DEMENTIA; HUMANS; INDANS; LEWY BODY DISEASE; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PHENYLCARBAMATES; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84861987193     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006504.pub2     Document Type: Review

References (116)

1. Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomized control trial. Journal of Neurology, Neurosurgery, and Psychiatry 2002;72:708-12.
2. Dubois B, Tolosa E, Kulisevsky J, Reichman H, Jones R, Burn D, et al. Efficacy and safety of donepezil in the treatment of Parkinson's disease patients with dementia. Alzheimer's and Parkinson's Disease Congress, Salzburg. 2007.
3. Burn D, Emre M, McKeith I. Reponse to rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease (EXPRESS study group). 57th Annual meeting American Academy of Neurology. April 2005. [http:www.abstracts2view.com/aan/]
4. Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Movement Disorders 2006; Vol. 21, issue 11:1899-907.
5. Dujardin K, Devos D, Duhem S, Destee A, Marie R-M, Durif F, et al. Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease. Journal of Neurology 2006; Vol. 253, issue 9:1154-9.
6. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, DeDeyn PP, et al. Rivastigmine for dementia associated with Parkinson's disease. New England Journal of Medicine 2004;351:2509-18.
7. Emre M, Onofrj M, Tekin S, Quarg P, Lane R, Express Study Group. Benefits of rivastigmine in Parkinson's disease dementia: Results from the EXPRESS study. Neurobiology of Aging 2004;25 Suppl 2:19.
8. Lees AJ. An extension study to investigate the effect of Exelon (rivastigmine) on Parkinson's disease dementia. National Research Register 2003.
9. Olin JT, Aarsland D, Meng X. Rivastigmine in the treatment of dementia associated with Parkinson's disease (PDD): subscale analysis of activities of daily living (ADL). Annals of Neurology. Conference: 134th American Neurological Association, ANA Meeting Baltimore, MD United States. October 2009. Conference Publication 2009; Vol. 66:S45.
10. Olin JT, Aarsland D, Meng X. Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living. Dementia and Geriatric Cognitive Disorders 2010; Vol. 29, issue 6:510-5.
11. Poewe W, EXPRESS Study Group. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: An open-label extension study. 57th Annual Meeting of the American Academy of Neurology, Miami Beach. April 2005.
12. Schmitt F, A, Aarsland D, Bronnick K, S, Xiangyi Meng Tekin S, et al. Evaluating rivastigmine in mild-to-moderate Parkinsons disease dementia using ADAS-cog items. American Journal of Alzheimer's Disease and other Dementias 2010; Vol. 25, issue 5:407-13.
13. Schmitt F, Farlow M, Olin J. Effects of rivastigmine on executive function in parkinson's disease dementia: Results from a 24-week placebo-controlled clinical trial. Annals of Neurology. Conference: 134th American Neurological Association, ANA Meeting Baltimore, MD United States. October 2009. Conference Publication 2009; Vol. 66 Suppl:48.
14. Schmitt FA, Aarsland D, Bronnick KS, Olin JT, Meng X. Evaluating cognitive effects of oral rivastigmine using subscales and items of the ADAS-cog in patients with mild to moderate Parkinson's disease dementia. American Journal of Geriatric Psychiatry. Conference: 2010 AAGP Annual Meeting Savannah, GA United States. March 2010. Conference Publication 2010; Vol. 18, issue 3 Suppl 1:79.
15. Schmitt FA, Aarsland DAG, Bronnick KS, Olin JT, Meng X. Evaluating cognitive effects of oral rivastigmine using subscales and items of the Adas-Cog in patients with mild to moderate Parkinson's disease dementia. Neurology 2010; Vol. 74, issue 9:A270.
16. Schmitt FA, Farlow MR, Meng X, Tekin S, Olin JT. Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementia. CNS Neuroscience & Therapeutics 2010; Vol. 16, issue 6:330-6.
17. Wesnes KA, McKeith I, Edgar C, Emre M, Lane R. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 2005;65:1654-6.
18. Leroi I, Brandt J, Reich SG, Lyketsos CG, Grill S, Thompson R, Marsh L. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. International Journal of Geriatric Psychiatry 2004;19(1):1-8.
19. Byrne J. Treatment of Lewy body dementia with Exelon. National Research Register 2000. [MEDLINE: http://www.update-software.com/NRR]
20. Del Ser T. Efficacy of cholinesterase inhibitors in lewy body dementia. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 5-8 April 2000, Stockholm, Sweden 2000:51.
21. Del Ser T, McKeith I, Anand R, Cicin-Sain A, Ferrara R, Spiegel R. Dementia with Lewy bodies: findings from an international multicentre study. International Journal of Geriatric Psychiatry 2000;15(11):1034-45.
22. McKeith I, Del Ser T, Anand R, et al. Rivastigmine provides symptomatic benefit in dementia with Lewy bodies: findings from a placebo-controlled international multicenter study. Neurology 2000e; Vol. 54 Suppl 3:A450.
23. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000f; Vol. 356, issue 9247:2031-6.
24. Rossor MN. A prospective, multicentre, randomised double blind placebo controlled exploratory study to evaluate the safety, tolerability and efficacy of a new drug in patients suffering from probable dementia with Lewy bodies. National Research Register http://www.update-software.com/NRR 1999.
25. Wesnes KA, McKeith IG, Ferrara R, Emre M, Del Ser T, Spano PF, et al. Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomised placebo-controlled international study using the Cognitive Drug Research computerized assessment system. Dementia and Geriatric Cognitive Disorders 2002;13:183-92.
26. Ravina B, Putt M, Siderow A, Farrar JT, Gillespie M, Crawley A, et al. Donepezil for dementia in Parkinson's disease: a randomised, double-blind, placebo controlled, crossover study. Journal of Neurology, Neurosurgery, and Psychiatry 2005;76(7):934-9.
27. Aarsland D. Galantamine for Parkinson's disease with dementia. European Neuropsychopharmacology 2002;12 Suppl:378-9.
28. Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. International Journal of Geriatric Psychiatry 2003;18(10):937-41.
29. Adler G, Christenn M, Bektas M, Ko-Inoshishi Y, Kupsch A, Scholz E, et al. Rivastigmine treatment in Parkinson's disease dementia: short-term cholinergic effects are correlated with six-month treatment response. Alzheimer's and Dementia. Conference: Alzheimer's Association International Conference, AAIC 11 Paris France. 16-21 July 2011. Conference Publication 2011; Vol. 7 Suppl 1, issue 4:776.
30. Anand R, Enz A, Novartis Pharmaceuticals Corporation. Effects of rivastigmine extend beyond symptomatic treatment in patients with Alzheimer's disease(AD): new clinical studies. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5-8, 2000; Stockholm, Sweden 2000:29.
31. Barone P, Burn DJ, van Laar T, Hsu C, Poewe W, Lane RM. Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients. Movement Disorders 2008; Vol. 23, issue 11:1532-40.
32. Barone P, De Deyn P, Emre M, Kulisevsky J, Poewe W, Pourcher E, et al. Baseline data from a long-term safety study of rivastigmine capsules and patch in mild to moderate Parkinson's disease dementia. Movement Disorders. Conference: 14th International Congress of Parkinson's Disease and Movement Disorders Buenos Aires Argentina. 13-17 June 2010. Conference Publication 2010; Vol. 25 Suppl:486-7.
33. Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clinical Neuropharmacology 2002;25(2):107-10.
34. Bergman J, Brettholz I, Shneidman M, Lerner V. Donepezil as add-on treatment of psychotic symptoms in patients with dementia of the Alzheimer's type. Clinical Neuropharmacology 2003;26(2):88-92.
35. Beversdorf DQ, Warner JL, Davis RA, Sharma UK, Nagaraja HN, Scharre DW. Donepezil in the treatment of dementia with Lewy bodies. American Journal of Geriatric Psychiatry 2004;12(5):542-4.
36. Brashear A, Kuhn ER, Lane KA, Farlow MR, Unverzagt FW. A double-blind placebo-controlled trial of donepezil in patients with Parkinson's disease and related dementia. Neurology 2004;62(7 Suppl):5.
37. Chung KA, Lobb BM, Nutt JG, Horak FB. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology 2010; Vol. 75, issue 14:1263-9.
38. Cummings J, Emre M, Aarsland D, Tekin S, Dronamraju N, Lane R. Effects of rivastigmine in Alzheimer's disease patients with and without hallucinations. Journal of Alzheimer's Disease 2010; Vol. 20, issue 1:301-11.
39. De Deyn P, Poewe W, Barone P, Emre M, Kulisevsky J, Pourcher E, et al. Results of a long-term safety study of rivastigmine capsules and patch in patients with mild to moderate dementia associated with Parkinson's disease. Neurodegenerative Diseases. Conference: 10th International Conference AD/PD - Alzheimer's and Parkinson's Diseases: Advances, Concepts and New Challenges Barcelona Spain. 9-13 March 2011. Conference Publication 2011; Vol. 8.
40. Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Lenzi GL, Meco G. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurological Sciences 2002;23:41-3.
41. Fogelson N, Kogan E, Korczyn AD, Giladi N, Shabtai H, Neufeld MY. Effects of rivastigmine on the quantitative EEG in demented parkinsonian patients. Acta Neurologica Scandinavica 2003;107(4):252-5.
42. Foy C. The non-dopaminergic neuropharmacology of idiopathic Parkinson's Disease. Thesis submitted in fulfilment for a Doctor of Philosophy, Section of Clinical Neurology, University of Sheffield (accessed from the British Library) 2000.
43. Grunewald RA. Investigation of the effects of rivastigmine on cognition in Parkinson's disease. National Research Register 1999.
44. Fujita Y, Takebayash M. Efficacy of low-dose donepezil for visual hallucinations in a patient with dementia with Lewy bodies. Psychiatry and Clinical Neurosciences 2010; Vol. 64, issue 3:336.
45. Giladi N, Shabtai H, Gurevich T, Benbunan B, Anca M, Korczyn AD. Rivastigmine for dementia in patients with Parkinson's disease. Acta Neurologica Scandinavica 2003;108:368-73.
46. Gustavsson A, Van Der Putt R, Jonsson L, McShane R. Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and Dementia with Lewy bodies. International Journal of Geriatric Psychiatry 2009; Vol. 24, issue 10:1072-8.
47. Hutchinson M, Fazzini E. Cholinesterase inhibition in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry 1996;61:324-5.
48. Korczyn AD, Shabati H, Benbunan B, Gurevich T, Anca M, Sidis S, Giladi N. The effect of treatment with rivastigmine (Exelon) on cognitive functions of patients with dementia and Parkinson's disease. Parkinsonism & Related Disorders 2001;7 Suppl:61.
49. Lanctot KL, Hermann N. Donepezil for behavioural disorders associated with Lewy bodies: a case series. International Journal of Geriatric Psychiatry 2000;15:183-8.
50. Linsarozo G, Lasa A, van Blercom N. Efficacy and safety of donepezil in cognitive impairment in Parkinson's disease: a pilot study. Clinical Neuropharmacology 2005;28(4):176-8.
51. Litvinenko IV, Odinak MM, Mogil'naya VI, Emelin AYU. Efficacy and safety of galantamine (Reminyl) for dementia in patients with Parkinson's disease (an open controlled trial). Neuroscience and Behavioral Physiology 2008; Vol. 38, issue 9:937-45.
52. McKeith IG. A pilot study into the effects of donepezil on cognitive impairment and neuropsychiatric features in patients with dementia with Lewy bodies and Parkinson's disease. National Research Register 2000a.
53. McLaren AT, Allen J, Murray A, Ballard CG, Kenny RA. Cardiovascular effects of donepezil in patients with dementia. Dementia and Geriatric Cognitive Disorders 2003;15:183-8.
54. Minett TS, Thomas A, Wilkinson LM, Daniel SL, Sanders J, Richardson J, et al. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. International Journal of Geriatric Psychiatry 2003;18(11):988-93.
55. Mori S, Mori E, Iseki E, Kosaka K. Efficacy and safety of donepezil in patients with dementia with Lewy bodies: preliminary findings from an open-label study. Psychiatry and Clinical Neurosciences 2006;60(2):190-5.
56. Olin JT, Bhatnagar V, Reyes P, Koumaras B, Meng X, et al. Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: A 26-week, open-label, prospective trial (Study ENA713B US32). International Journal of Geriatric Psychiatry 2010; Vol. 25, issue 4:419-26.
57. Pakrasi S, Thomas A, Mosimann UP, Cousins DA, Burn DJ, O'Brien JT, McKeith IG. Cholinesterase inhibitors in advanced dementia with Lewy bodies: increase or stop?. International Journal of Geriatric Psychiatry 2006;21(8):719-21.
58. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of Parkinson's psychosis and cognitive impairment: preliminary findings from an open trial. Movement Disorders 2001;16:1171-95.
59. Rektorova I. Effect of donepezil on dementia in Parkinson's disease and Alzheimer's disease: a pilot study [Ucinek donepezilu na demenci u parkinonovy nemoci a alzheimerovy nemoci. pilotni studie]. Ceska a Slovenska Neurologie a Neurchirurgie 2004;67(5):359-63.
60. Rosengarten B, Dannhardt V, Burr O, Pohler M, Rosengarten S, Oechsner M, et al. Neurovascular coupling in Parkinson's disease patients: effects of dementia and acetylcholinesterase inhibitor treatment. Journal of Alzheimer's Disease 2010; Vol. 22, issue 2:415-21.
61. Samuel W, Caligiuri M, Galasko D, Lacro J, Marini M, McClure FS, et al. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: A preliminary study. International Journal of Geriatric Psychiatry 2000; Vol. 15, issue 9:794-802.
62. Satoh M, Ishikawa H, Meguro K, Kasuya M, Ishii H, Yamauchi S. Improved visual hallucination by donepezil and occipital glucose metabolism in dementia with Lewy bodies: the Osaki-Tajiri project. European Neurology 2010; Vol. 64, issue 6:337-44.
63. Thomas AJ, Burns A, Rowan EN, Littlewood E, Newby J, Cousins D, et al. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies. International Journal of Geriatric Psychiatry 2005;20(10):938-44.
64. Touchon J, Bergman H, Bullock R, Rapatz G, Nagel J, Lane R. Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology. Current Medical Research and Opinion 2006;22(1):49.
65. Touchon J, Bergman H, Bullock R. Erratum: Response to rivastigmine or donepezil in Alheimer's patients with symptoms suggestive of concomitant Lewy body pathology. Current Medical Research and Opinion 2006;22(1):45.
66. Van Laar T, de Vries JJ, Nakhosteen A, Leenders KL. Rivastigmine as anti-psychotic treatment in patients with Parkinson's disease. Parkinsonism & Related Disorders 2001;7 Suppl:73.
67. Vasile D, Vasiliu O, Vasile ML, Terpan M, Grigorescu G, Bogdan V, et al. Comparative efficacy of cholinesterase inhibitors in dementia associated with Parkinson's disease. European Neuropsychopharmacology. Conference: 23rd European College of Neuropsychopharmacology, ECNP Congress Amsterdam, Netherlands. 28 August to 1 September 2010. Conference Publication 2010; Vol. 20 Suppl:553-4.
68. Vasile D, Vasiliu O. Management of cognitive symptoms in dementia associated with Parkinson's disease. Proceedings of the World Medical Conference 2010:284-6.
69. Walker Z. Lewy body dementia: The investigation of pre and post synaptic dopaminergic receptors with SPET. NRR 2000. [MEDLINE: http://www.doh.gov.uk/nrr.htm]
70. Werber EA, Rabey JM. The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. Journal of Neural Transmission 2001;108(11):1319-25.
71. Wilcock GK. A double-blind, placebo-controlled, randomised, parallel group phase IIa study of the efficacy and safety of a novel therapy in the treatment of behavioural and psychological symptoms in subjects with dementia with Lewy bodies. National Research Register 2000e.
72. Anon. Donepezil to treat dementia in Parkinson's disease. ClinicalTrials.gov 2004.
73. Anon. Double-blind study of E2020 in patients with dementia with Lewy bodies - Phase II. ClinicalTrials.gov 2007.
74. Anon. A study of E2020 in patients with dementia with Lewy bodies (DLB), followed by a long-term extension phase - Phase III. ClinicalTrials.gov 2011.
75. Burn DJ. Multi-centre UK study of the acetylcholinesterase inhibitor donepezil in early dementia associated with Parkinson's disease (MUSTARDD-PD). ClinicalTrials.gov: http://clinicaltrials.gov/ct2/show/NCT01014858 2009.
76. Kuran R. Treatment of agitation/psychosis in dementia/parkinsonism. Alzheimer's Disease Education and Referral Centre (ADEAR) 2003.
77. Marion MH. An open 24 week prospective, randomised, double-blind placebo controlled parallel group study of efficacy, tolerability and safety of 3-12mg/day of Exelon and Exelon (rivastigmine) capsules in patients with Parkinson's disease dementia. National Research Register 2003.
78. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Archives of Neurology 2003;60:387-92.
79. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Movement Disorders 2005;20:1255-63.
80. Ballard C, Ziabreva I, Perry R, Larsen JP, O'Brien J, McKeith I, et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 2006;67(11):1931-4.
81. Barr A, Brandt J. Word-list generation deficits in dementia. Journal of Clinical and Experimental Neuropsychology 1996;18:810-22.
82. Bedard MA, Agid Y, Chouinard S, et al. Mental and Behavioural dysfunction in movement disorders. Totowa, NJ: Humana Press, 2003.
83. Beery KE. Revised Administration, Scoring and Teaching Manual for the Developmental Test of Visual-Motor Integration. Cleveland: Modern Curriculum Press, 1989.
84. Bostrom F, Jonsson L, Minthon L, Londos E. Patients with Lewy body dementia use more resources than those with Alzheimer's disease. International Journal of Geriatric Psychiatry 2006; Vol. 22, issue 8:713-9.
85. Braak H, Rub U, Del Tredici K. Cognitive decline correlates with neuropathological stage in Parkinson's disease. Journal of the Neurological Sciences 2006;248(1-2):255-8.
86. Brandt J, Benedict RHB. Hopkins Verbal Learning Test-Revised, Professional Manual. Odessa, FL: Psychological Assessment Resources, Inc., 2001.
87. Burn DJ, McKeith IG. Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease. Movement Disorders 2003;18 Suppl 6:72-9.
88. Burn DJ. Cortical Lewy body disease and Parkinson's disease dementia. Current Opinions in Neurology 2006;19(6):572-9.
89. Cummings JL, Mega M, Gray K, Rosenburg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-13.
90. Delis DC, Kaplan E, Kramer JH. Delis-Kaplan executive function system. San Antonio, Tex.: Psychological Corporation, 2001.
91. Dubois B, Pillon B. Cognitive deficits in Parkinson's disease. Journal of Neurology 1997;244:2-8.
92. Fahn S, Elton RS, Members of the UPDRS Develpment Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Goldstein M editor(s). Recent Developments in Parkinson's Disease II. New York: Macmillan, 1987:153-63.
93. Folstein NF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975;12:189-98.
94. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders 1997;11 Suppl 2:533-9.
95. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Chichester (UK): John Wiley & Sons, 2008.
96. Jellinger KA, Bancher CH, Fischer P. Neuropathological correlates of mental dysfunction in Parkinson's disease. In: Wolters EC, Scheltens PH editor(s). Mental Dysfunction in Parkinson's Disease. Dordrecht: ICG Printing, 1994:141-61.
97. Lee VM, Trojanowski JQ. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron 2006;52(1):33-8.
98. Lippa CF, Johnson R, Smith TW. The medial temporal lobe in dementia with Lewy bodies: a comparative study with Alzheimer's disease. Annals of Neurology 1998;43(1):102-6.
99. Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson's disease dementia. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD004747.pub2]
100. Manos PJ, Wu R. The ten point clock drawing test: a quick screen and grading method for cognitive impairment in medical and surgical patients. International Journal of Psychiatry in Medicine 1994;24:229-44.
101. Mattis S. Dementia Rating Scale (DRS) Professional Manual. Odessa, FL: Psychological Assessment Resources, Inc., 1988.
102. McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992;305:673-8.
103. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-24.
104. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies. Third report of the DLB consortium. Neurology 2005;65:1863-72.
105. Nakano I, Hirano A. Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease. Annals of Neurology 1984;15:415-8.
106. Olanow CW, McNaught KS. Ubiquitin-proteasome system and Parkinson's disease. Movement Disorders 2006;21(11):1806-23.
107. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:790-812.
108. Perry EK, Haroutunian V, Davis KL, et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. NeuroReport 1994;5(7):747-9.
109. Reitan RM. Validity of the Trail Making Test as an indicator of organic brain damage. Perceptual and Motor Skills 1958;8:271-6.
110. Rosen WG, Mohs RC, Davis K. A new rating scale for Alzheimer's disease. American Journal of Psychiatry 1984;141:1356-64.
111. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change. Alzheimer Disease and Associated Disorders 1997;11 Suppl 2:22-32.
112. Schretlen D. Brief Test of Attention Professional Manual. Odessa, FL: Psychological Assessment Resources, Inc., 1997.
113. Simpson PM, Surmon DJ, Wesnes KA, Wilcock GK. The cognitive assessment system for the demented patients: a validation study. International Journal of Geriatric Psychiatry 1991;6:95-102.
114. Wild R, Pettit T, Burns A. Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: 10.1002/14651858.CD003672]
115. Williams SS, Williams J, Combrinck M, Christie S, Smith AD, McShane R. Olfactory impairment is more marked in patients with mild dementia with Lewy bodies than those with mild Alzheimer disease. Journal of Neurology, Neurosurgery, and Psychiatry 2009;80(6):667-70.
116. Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age and Ageing 2005;34:561-6.